INC Research Strengthens Oncology Division with Proven Leadership

RALEIGH, N.C.--(BUSINESS WIRE)--INC Research ®, Inc., a therapeutically-focused contract research organization (CRO) with a process for delivering reliable results, today announced Nick Kenny, Ph.D. as the senior vice president of Oncology. Dr. Kenny began his career at INC Research in 2006 as senior project director Oncology. He was quickly promoted to executive director of Oncology in 2007. Earlier this year, he was named vice president of Oncology where he has proven his ability to drive the overall strategy and direction for this significant division for the CRO.

“Nick was the obvious choice to step into this senior management role in oncology,” said John Potthoff, COO of INC Research. “Not only does he have impeccable therapeutic expertise, but he has been instrumental in fine tuning the methodologies that we use today in our Trusted Process for delivering high quality clinical results that meet or exceed customer expectations. We are confident that Nick can continue to build our successful oncology practice.”

Dr. Kenny has 25 years of research, development and international project integration experience in the CRO and academic segments. Prior to INC Research, he held various management positions at CROs where he established the strategic direction of clinical programs, as well as global oversight of project management, clinical monitoring and regulatory staff. Prior to his move to industry, Dr. Kenny spent 15 years in endocrinology and cell biology research and teaching in the UK, Canada, and the United States where he was assistant professor in the College of Medicine at the University of Vermont. Over the past 10 years, Dr. Kenny’s drug development expertise has been primarily focused upon oncology clinical development. He is continually sought after as a subject matter expert to represent both CRO and oncology perspectives by industry publications and conferences.

“I am thrilled to be working with a CRO that is as passionate about oncology drug development as I am,” said Kenny. “INC Research has developed an incredible track record for global oncology trials. I intend to reinforce that reputation by continued advancement of the quality of service and depth of expertise the oncology practice offers to support our customers in bringing forward new treatments for cancer patients.”

INC Research is committed to supporting new and better therapeutic options for oncology drug treatments. The CRO has conducted more than 300 Phase I-IV oncology trials that investigated over 140 new and various anticancer therapies. Global studies have included almost 26,000 cancer patients in more than 3,200 investigative sites.

About INC Research^® Inc.

INC Research is a therapeutically-focused contract research organization with a high performance reputation for conducting global clinical development programs of the highest integrity. Pharmaceutical and biotechnology companies look to INC Research for a complete range of customized Phase I through Phase IV programs in therapeutic areas of specialty, and in innovative pediatric and women’s health trials. The company’s “The Trusted Process^®” methodology and therapeutic foresight leads customers to more confident, better-informed drug and device development decisions. INC Research is headquartered in Raleigh, North Carolina, with 25 office locations and a presence in 32 countries worldwide. For more information please visit www.incresearch.com.